The 2024 MM+M Awards winners; Pfizer announces a combination of its drugs prolonged the lives of patients with a type of advanced prostate cancer; Gritstone Bio files for Chapter 11 bankruptcy.
Five things for pharma marketers to know for Thursday morning
GSK spends $2.2 billion to settle lawsuits over heartburn medication Zantac causing cancer; Illumina rolls out cheaper, smaller versions of gene sequencers; GLP-1s could cost Medicare $35 billion over eight years.
Five things for pharma marketers to know for Wednesday morning
GSK, Pfizer RSV vaccine sales fall in U.S.; Vice President Kamala Harris proposes a new Medicare benefit for in-home eldercare; Former President Donald Trump secretly sent rare COVID tests from to Russian President Vladimir Putin.
Five things for pharma marketers to know for Monday morning
Eli Lilly’s Mounjaro has limited availability through February; Samsung Biologics says its net profit fell 21.4% in Q4 2023 due largely to a one-off factor; The FDA denies approval for a newer formulation of tesamorelin that Theratechnologies proposed.
Five things for pharma marketers to know for Monday morning
Will Bernie Sanders subpoena Big Pharma execs?; Drugmakers raise the list prices for Ozempic and Mounjaro; Scientists identify a persistent change in a handful of blood proteins in people with long COVID.
Five things for pharma marketers to know on Tuesday morning
Novartis in talks to buy Cytokinetics; Boston Scientific acquires medtech company Axonics in $3.7 billion deal; Lilly’s Zepbound obesity drug reaches 25,000 new prescriptions mark.
Five things for pharma marketers to know on Tuesday
Medical complications rise at hospitals bought by PE firms; BMS snaps up radiation cancer therapy firm; Government ban on certain Apple Watches kicks in.